Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.

Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group.

Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10.

PMID:
31290569
2.

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST.

Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.

3.

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.

Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M.

Haematologica. 2017 Nov;102(11):1913-1922. doi: 10.3324/haematol.2017.173583. Epub 2017 Sep 21.

4.
5.

[A woman with low hemoglobin values].

Riedl JA, Berenschot H.

Ned Tijdschr Geneeskd. 2010;154:A1035. Dutch.

PMID:
20619051
6.

Enteroviral encephalitis in a patient with a marginal zone lymphomatreated with rituximab.

Schilthuizen C, Berenschot HW, Levin MD.

Neth J Med. 2010 May;68(5):221-3.

7.

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON).

Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30.

PMID:
19880501
8.

Measurement of total homocysteine concentrations in acidic citrate- and EDTA-containing tubes by different methods.

Willems HP, den Heijer M, Lindemans J, Berenschot HW, Gerrits WB, Bos GM, Blom HJ.

Clin Chem. 2004 Oct;50(10):1881-3. No abstract available.

PMID:
15388669
10.

[25 years of kidney replacement treatment at a general hospital].

Gerlag PG, Berenschot H, Deckers PF.

Ned Tijdschr Geneeskd. 1989 Jul 1;133(26):1318-22. Dutch.

PMID:
2674733
11.

[Anal disorders as the initial and only expression of Crohn's disease].

Verhagen PF, Berenschot H, Breteler L.

Ned Tijdschr Geneeskd. 1988 Oct 8;132(41):1873-5. Dutch. No abstract available.

PMID:
3185779

Supplemental Content

Loading ...
Support Center